With clinical-grade accuracy, quality, and turnaround time, PCDx delivers a comprehensive NGS-based analysis and report that includes information on DNA mutations, copy number variations, mRNA expression and protein expression.Continue reading
NGS is a revolutionary laboratory technology that is utilized by Paradigm’s PCDx test to rapidly, accurately and confidently assess genes of a specific tumor sample and identify potentially treatable genomic alterations in cancer’s DNA.
The PCDx test is a Next-Generation Sequencing based diagnostic genetic test that offers a more targeted, personalized approach to cancer treatment by interrogating and identifying the underlying genomic and proteomic alterations of a patients tumor’s DNA & protein. The information provided by this test assists ordering physicians in developing a more informed and individually tailored treatment strategy for a patient’s cancer.
The Paradigm’s NGS-based PCDx tumor profiling test provides three key clinical advantages:
The Paradigm PCDx test is typically utilized for patients when first-line or second-line treatment or standard of care options are not working. This is typically referred to as “refractory” disease. PCDx is also utilized for patients with cancers that are rare or of an aggressive nature with limited treatment options. Ultimately, however, it is up to the ordering clinician as to whether PCDx testing may be appropriate for your patient.
The PCDx Report will provide the following information:
Once your sample is received for testing, test results should be available within 4-5 business days.
The Paradigm PCDx test may be performed on the following:
The Paradigm PCDx test is performed in our CLIA certified laboratory in Phoenix, AZ to ensure the highest standards of laboratory practice. Furthermore, each individual report is reviewed and commented on by an experienced oncologist and pathologist in a fashion intended to clarify the results for the ordering physician to aid in their decision making.